4d agoGuruFocusBULLISH 56Analyst
PRAX Reiterated by BTIG -- Price Target Maintained at $826
Praxis Precision Medicine (PRAX) Analyst Rating Update On October 03, 2023, BTIG reaffirmed its "Buy" rating for Praxis Precision Medicine (PRAX) and maintai
Archived explainer. For the current picture see today's PRAX page.
Why Is PRAXIS PRECISION MED (PRAX) Stock Up Today?
By the Top Tier Newswire AI Desk · November 9, 2026 at 2:02 PM ET · reviewed against 5 wire stories
PRAXIS PRECISION MED (PRAX) is up +16.25% in the latest session. Our newswire has captured 5 stories on PRAX across 5 sources in the last 36 hours, with AI sentiment reading mixed (avg 57/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Praxis Precision Medicine shares surged 16.25% to $322.72, driven by third-quarter earnings that beat expectations and a reaffirmed bullish outlook from major analysts. The stock closed near its session high after reporting non-GAAP EPS of -$3.23, which exceeded estimates by $0.40.
What Happened
Praxis Precision Medicine reported third-quarter 2026 financial results, disclosing that cash and investments totaled approximately $1.3 billion as of September 30, 2026. This liquidity position is expected to fund operations into 2028. The company also confirmed that FDA reviews are ongoing for relutrigine, with a PDUFA target action date of December 27, 2026, and ulixacaltamide HCI, with a PDUFA target action date of January 29, 2027.
Following the release, BTIG reiterated its "Buy" rating and maintained a price target of $826. Raymond James also reiterated a "Strong Buy" rating on the stock. The company filed a Form 8-K with the SEC to disclose the results of operations and financial condition.
What The Data Shows
The stock opened at $285.00, a 2.7% gap up from the prior close of $277.62. Intraday trading saw a session low of $279.14 at 9:35 AM ET and a session high of $324.80 at 2:00 PM ET. Volume reached 0.5 million shares, which is 1.2 times the three-month daily average. The stock has printed 24 fresh 52-week highs and 4 fresh 52-week lows on November 9, 2026.
Fundamentals show a market cap of $7.8 billion with trailing twelve-month revenue up 365.0%. The company remains unprofitable with a trailing twelve-month EPS of -$12.86 and a beta of 2.84. The 52-week range is $159.74 to $392.70. Over the last eight sessions, the stock moved 7.8% from $264.49 to $285.06. Congressional disclosures show four buys and zero sells in the last 90 days, with the most recent filing on October 12, 2026.
What To Watch
Investors will monitor the FDA review process for relutrigine and ulixacaltamide HCI. The next scheduled PDUFA target action date for relutrigine is December 27, 2026.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
PRAX by the numbers
Last: $322.72Session: +16.25%7 sessions: +7.78%Coverage: 5 stories / 5 sourcesAI sentiment: 57/100 (mixed)Mkt cap: $7.8B52w: $159.74 to $392.70
The headlines behind the move
4d agoInvesting.com Analyst RatingsBULLISH 63Analyst
Raymond James reiterates Strong Buy on Praxis Precision Medicines stock
Raymond James reiterates Strong Buy on Praxis Precision Medicines stock
4d agoSeeking AlphaBULLISH 64Earnings
Praxis Precision Medicines Non-GAAP EPS of -$3.23 beats by $0.40
Praxis Precision Medicines tops Q3 EPS estimates and boosts cash to $1.3B, funding operations into 2028.
4d agoSEC 8-KNEUTRAL 50General
Praxis Precision Medicines, Inc. (PRAX) files 8-K
Filed: 2026-11-09 AccNo: 0001689548-26-000086 Size: 260 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
4d agoBusiness InsiderNEUTRAL 52Earnings
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2026 Financial Results
FDA reviews of relutrigine, with PDUFA target action date of December 27, 2026, and ulixacaltamide HCI, with PDUFA target action date of January 29, 2027, are ongoing
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on PRAX: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier PRAX move explainers: 2026-11-10 · 2026-11-09 · 2026-08-17 · 2026-08-07 · 2026-08-06